Shares of Inspire Medical Systems (NYSE:INSP) Inc. experienced a significant surge, climbing up to 12% following the company's announcement that it anticipates weight-loss medications to expand the number of eligible candidates for its sleep apnea treatment device.
The medical-device maker's CEO, Timothy P. Herbert, addressed the Morgan Stanley Healthcare Conference, highlighting the issue that many patients are currently ineligible for Inspire therapy due to their high Body Mass Index (BMI).
Herbert explained that the company is actively engaging with physicians to increase awareness about the benefits of GLP-1 medications. These drugs are intended to aid in weight loss, which can subsequently decrease the severity of obstructive sleep apnea, making more patients suitable for the company's implant.
He emphasized that while GLP-1 drugs are not directly aimed at treating obstructive sleep apnea, they can play a supportive role in managing the condition by helping patients reduce their BMI.
The CEO's remarks at the conference underscore the potential for these weight-loss drugs to indirectly benefit Inspire Medical by increasing the pool of patients who can qualify for their sleep apnea implant. This development is particularly relevant for those who have been previously unable to receive the therapy due to weight restrictions associated with a high BMI.
Inspire Medical's focus on collaboration with healthcare professionals to educate them about the GLP-1 drugs' weight loss benefits reflects the company's strategy to widen its market reach. This approach aims to facilitate access to its sleep apnea treatment for a larger segment of patients who suffer from this condition.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.